Prevention of Allergic Diseases in Infants

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,170

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2026

Conditions
Atopic Diseases
Interventions
OTHER

Hydrolyzed Formula

Infant formula with extensively hydrolyzed proteins and pre- and probiotics.

OTHER

Control formula

Infant formula with intact proteins and pre- and probiotics.

Trial Locations (14)

Unknown

Second specialized obstetric and gynecological hospital for active treatment Sheinovo EAD, Sofia

Nemocnice Strakonice, a.s., Strakonice

Suomen Terveystalo Oy, Tampere

CHU Estaing, Clermont-Ferrand

Charité Universitätsmedizin Berlin, Berlin

Klinik für Kinder- und Jugendmedizin der Ruhruniversität Bochum im St. Josef Hospital, Bochum

Studienambulanz der pädiatrische Pneumologie und AllergologieKlinik für Kinder- und Jugendmedizin (KKJM), Frankfurt

Klinik für Kinder und Jugendmedizin, Hamm

Klinik für Kinder- und Jugendmedizin Marienhospital gGmbH Wesel, Wesel

Unità Allergologia-Unità Allergologia-, Roma

Instytut Mikroekologii, Poznan

Hospital braga, Braga

"Clinical Hospital Center Dr Dragisa Misovic-Dedinje", Belgrade

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

All Listed Sponsors
lead

HiPP GmbH & Co. Vertrieb KG

INDUSTRY

NCT03489733 - Prevention of Allergic Diseases in Infants | Biotech Hunter | Biotech Hunter